CGTX.US Cognition Therapeutics Inc

Healthcare Biotechnology USA Stocks
0.6798 USD
Close of Nov 14, 2026
0.5500 1.81
Market cap
USD 64.6M
P/E
-
P/B
2.20x
ROE
-57.6%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is CGTX.US undervalued?

Graham number

The Graham number of Cognition Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Cognition Therapeutics Inc fundamental analysis

No fundamental analysis for Cognition Therapeutics Inc yet.

Cognition Therapeutics Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Cognition Therapeutics Inc

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is zervimesine, an orally delivered small molecule to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, which is in Phase 2 clinical studies for the treatment of Alzhe…

Full company profile